Cour Pharma
5 known investors
Find your way into Cour Pharma
COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.
Investors Β· 5
Competitors Β· 3
by search overlap
Collegium Pharmaceutical34 shared keywordsCollegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions. It serves patients living with serious medical conditions and the healthcare professionals caring for them.
Kite Pharma30 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Bioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Cour Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cour Pharma do?
- COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function. The company is advancing a pipeline of disease-modifying therapies aimed at patients with a range of autoimmune conditions.
- Who are Cour Pharma's investors?
- Cour Pharma's investors include Alpha Wave Global, Lumira Ventures, Roche Venture Fund, Angelini Ventures, JDRF T1D Fund.